A Study of PARG Inhibitor IDE161 in Participants with Advanced Solid Tumors
Contact:
NCT Number:
Protocol:
AAAU8115
Study Status:
Active/Enrolling
Population:
Adult
Phase:
I
The purpose of this study is to find out if the experimental study drug called IDE161 used alone is safe and helpful in solid tumors known to be caused by an error in genes that repair DNA. Cells have different ways to repair damaged DNA. Experimental means that the study drug has not been approved by any regulatory authorities, including the U.S. Food and Drug Administration (FDA) .IDE161 may block the ability of a protein called Poly(ADP-ribose) glycohydrolase (PARG) from properly functioning. PARG is an important protein in a different DNA repair pathway called Base Excision Repair (BER). This is the first time IDE161 will be given to people.
Are you Eligible? (Inclusion Criteria)
- You are 18 years of age or older 2. You are able to safely administer and retain orally administered study treatment. 3. You have not had major surgery within 4 weeks prior to enrollment.
Specialty Area(s)
Bladder Cancer , Breast Cancer, Colon and Rectal Cancer, Esophageal Cancer, Gynecologic Cancers, Cervical Cancer, Ovarian Cancer, Liver Cancer, Lung cancer, Skin cancers, Melanoma, Pancreatic Cancer, Prostate Cancer, Stomach Cancer, Testicular Cancer, Thyroid Cancer
Principal Investigator
Trial Location(s)
CUIMC/Herbert Irving Pavilion
161 Fort Washington Avenue
New York, NY 10032
